Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/35453
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCandel, Francisco Javier-
dc.contributor.authorCanton, Rafael-
dc.contributor.authorCanton, Rafael-
dc.contributor.authorDel Pozo, Jose L-
dc.contributor.authorGalán Sánchez, Fátima-
dc.contributor.authorNavarro, David-
dc.contributor.authorRODRIGUEZ DIAZ, JUAN CARLOS-
dc.contributor.authorRODRIGUEZ DIAZ, JUAN CARLOS-
dc.contributor.authorRodríguez Aguirregabiria, Montserrat Aránzazu-
dc.contributor.authorSuberviola, Borja-
dc.contributor.authorZaragoza, Rafael-
dc.contributor.otherDepartamentos de la UMH::Producción Vegetal y Microbiologíaes_ES
dc.date.accessioned2025-01-29T08:52:59Z-
dc.date.available2025-01-29T08:52:59Z-
dc.date.created2024-12-30-
dc.identifier.citationCritical care 2024 Dec 30;28(1):440es_ES
dc.identifier.issn1364-8535-
dc.identifier.issn1466-609X-
dc.identifier.urihttps://hdl.handle.net/11000/35453-
dc.description.abstractRapid multiplex molecular syndromic panels (RMMSP) (3 or more pathogens and time-to-results < 6 h) allow simultaneous detection of multiple pathogens and genotypic resistance markers. Their implementation has revolutionized the clinical landscape by significantly enhancing diagnostic accuracy and reducing time-to-results in different critical conditions. The current revision is a comprehensive but not systematic review of the literature. We conducted electronic searches of the PubMed, Medline, Embase, and Google Scholar databases to identify studies assessing the clinical performance of RMMSP in critically ill patients until July 30, 2024. A multidisciplinary group of 11 Spanish specialists developed clinical questions pertaining to the indications and limitations of these diagnostic tools in daily practice in different clinical scenarios. The topics covered included pneumonia, sepsis/septic shock, candidemia, meningitis/encephalitis, and off-label uses of these RMMSP. These tools reduced the time-to-diagnosis (and therefore the time-to-appropriate treatment), reduced inappropriate empiric treatment and the length of antibiotic therapy (which has a positive impact on antimicrobial stewardship and might be associated with lower in-hospital mortality), may reduce the length of hospital stay, which could potentially lead to cost savings. Despite their advantages, these RMMSP have limitations that should be known, including limited availability, missed diagnoses if the causative agent or resistance determinants are not included in the panel, false positives, and codetections. Overall, the implementation of RMMSP represents a significant advancement in infectious disease diagnostics, enabling more precise and timely interventions. This document addresses relevant issues related to the use of RMMSP on different critically ill patient profiles, to standardize procedures, assist in making management decisions and help specialists to obtain optimal outcomeses_ES
dc.formatapplication/pdfes_ES
dc.format.extent24es_ES
dc.language.isoenges_ES
dc.publisherBioMed Centrales_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCritically ill patientes_ES
dc.subjectInfectiones_ES
dc.subjectMultidrug resistant pathogenses_ES
dc.subjectSeptic shockes_ES
dc.subjectSepsises_ES
dc.subjectBloodstream infectiones_ES
dc.subjectSyndromic molecular diagnosises_ES
dc.titleThe role of rapid multiplex molecular syndromic panels in the clinical management of infections in critically ill patients: an experts-opinion documentes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1186/s13054-024-05224-3es_ES
Appears in Collections:
Artículos Producción vegetal y microbiología


Thumbnail

View/Open:
 02 - Candel FJ et al crit Care.pdf

1,79 MB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???